SecBot SecBot
8-K ·Filed Nov 9, 2026

IMA

ImageneBio, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed7d 11h ago SEC0001193125-26-453639
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor the initiation of the Phase 2 alopecia areata study by year-end 2026 and any updates on the ADAPTIVE trial enrollment. The reduced cash burn extends the runway, but the company remains pre-revenue with no near-term catalyst until ADAPTIVE topline data in Q4 2027.

DirectionNeutral
Confidencehigh
Horizonmonths

Drug in focus

IMA drug pipeline →

olevaprubart

● Neutral Named in this 8-K
Impact
Phase
Phase 2b
Time to market
If the Phase 2b ADAPTIVE trial (topline Q4 2027) succeeds, a Phase 3 program would follow, meaning potential approval is likely several years away, probably no earlier than 2029-2030.
Next catalyst
None dated

What to watchThe next hard catalyst is the Phase 2b ADAPTIVE topline readout in atopic dermatitis, expected in Q4 2027, over a year away. In the nearer term, watch for initiation of the Phase 2 alopecia areata study by year-end 2026 and any early efficacy signals. The OX40 competitive landscape is shifting rapidly with Sanofi's amlitelimab setback and AbCellera's exit, which could be a relative positive for olevaprubart's positioning.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$3.81
T+0 close · Nov 9, 2026 · via day close
Latest settled
−2.36%
T+1 · $3.72 · next T+5 in 4h
Vs SPY
−3.68%
α at T+1
Latest observation
−14.16%
T+4 · FF3 residual α
  1. T+0 · Nov 10 $3.81entry
  2. T+1 · 6d ago −2.36%α −3.68% · $3.72
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ImageneBio reported Q3 2026 net loss of $15.6M ($0.91 per share), narrower than the $24.8M loss ($2.91 per share) in Q3 2025, driven by lower R&D and G&A expenses. The Phase 2b ADAPTIVE trial in atopic dermatitis continues as planned with topline data expected in Q4 2027, and a Phase 2 alopecia areata study is on track to start by year-end 2026. Cash of $126.6M provides runway into Q1 2028.

Key Financial Metrics

EPS
−$0.91
est −$0.85 · -7.1%
Revenue
$0.00
est $0.00
Rating
miss

Key Facts

  • Net loss of $15.6M for Q3 2026 vs $24.8M for Q3 2025
  • Net loss per share $0.91 vs $2.91 in prior year period
  • Cash, cash equivalents and marketable securities of $126.6M as of Sep 30, 2026
  • R&D expenses $11.3M vs $15.2M in Q3 2025
  • G&A expenses $6.0M vs $11.0M in Q3 2025
  • Phase 2b ADAPTIVE trial topline data expected Q4 2027
  • Phase 2 alopecia areata study on track to initiate by end of 2026
  • No cases of Kaposi sarcoma observed across all clinical trials to date

Financial Impact

Net loss improved by $9.2M year-over-year; cash burn rate appears reduced with lower operating expenses

net losscash positionR&D expensesG&A expenses

Risk Factors

  • Pre-revenue clinical-stage biotech with no approved products or revenue stream
  • Single pipeline asset (olevaprubart/IMG-007) concentration risk
  • ADAPTIVE trial topline data not expected until Q4 2027, over a year away
  • Potential need for additional capital before reaching key data milestones

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-453639
Document: d139863d8k.htm0001193125-26-453639
Document: 0001193125-26-453639-index-headers.html0001193125-26-453639
Document: 0001193125-26-453639-index.html0001193125-26-453639
Document: 0001193125-26-453639.txt0001193125-26-453639
8-K Data (Synthetic)0001193125-26-453639

Track record

10 reports on IMA

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +27.94% at T+60 after the Aug 7, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $3.50 Now $3.20 −8.57% settles Feb 12
  2. Nov 9, 20267d ago 8-K Neutral 4/10 Viewing Entry $3.81 Now $3.20 −16.01% settles Feb 8
  3. Aug 7, 202614w ago EFFECT Bearish 5/10 Entry $5.69 to $4.10 Now $3.20 +43.76% ▲ +27.94% +25.81% vs SPY
  4. Jun 26, 202620w ago 8-K Neutral 3/10 Entry $6.07 to $4.85 Now $3.20 −47.28% ▼ −20.10% −24.48% vs SPY
  5. Apr 30, 202628w ago DEFA14A Neutral 3/10 Entry $5.66 to $5.76 Now $3.20 −43.46% ▲ +1.77% −1.30% vs SPY
  6. Apr 13, 202631w ago 8-K Bearish 6/10 Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
  7. Apr 13, 202631w ago Press Release Bearish 6/10 Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
  8. Apr 6, 202632w ago EFFECT Neutral 3/10 Entry $4.55 to $5.77 Now $3.20 −29.67% ▲ +26.81% +13.34% vs SPY
  9. Mar 17, 202634w ago Press Release Neutral 3/10 Entry $5.83 to $5.71 Now $3.20 −45.06% ▼ −1.97% −13.50% vs SPY
  10. Mar 10, 202635w ago Press Release Neutral 4/10 Entry $6.07 to $5.45 Now $3.20 −47.28% ▼ −10.21% −21.90% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens in 6h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026